Larch arabinogalactan effects on reducing incidence of upper respiratory infections

Figures & data

Figure 1.  Subject flow.

Table 1.  Baseline characteristics of the arabinogalactan and the placebo groups (FAS).

	All	Arabinogalactan	Placebo	p
	(n = 199)	(n = 101)^y	(n = 98)^z
	mean ± SD	mean ± SD	mean ± SD
Sex (M/F)	65/134	37/64	28/70	0.225
Age (years)	42.2 ± 15.4	42.0 ± 14.9	42.4 ± 15.8	0.911
Height (cm)	171.1 ± 8.3	170.7 ± 9.0	171.6 ± 7.7	0.417
Weight (kg)	70.2 ± 11.8	69.5 ± 12.5	70.9 ± 11.2	0.240
BMI (kg/m^2)	23.9 ± 2.9	23.7 ± 3.0	24.0 ± 2.7	0.487
Systolic blood pressure (mmHg)	123.5 ± 15.1	123.9 ± 15.8	123.2 ± 14.6	0.742
Diastolic blood pressure (mmHg)	78.5 ± 7.1	78.8 ± 7.3	78.2 ± 6.8	0.636
Heart rate (1/min)	71.3 ± 6.9	71.4 ± 7.0	71.2 ± 6.9	0.795
Body temperature (°C)	36.6 ± 0.3	36.6 ± 0.3	36.5 ± 0.3	0.188

SD = standard deviation.

^yExcluding three subjects’ data (withdrawn due to abnormal laboratory values [n = 2], no efficacy data after baseline [n = 1]).

^zExcluding two subjects data (withdrawn due to abnormal laboratory values [n = 1], no efficacy data after baseline [n = 1]).

Figure 2.  Incidence of common cold infections following 12 week arabinogalactan or placebo supplementation according to the FAS and the PP population. Values are mean ± SD.